Bill Ackman‘s Pershing Square has filed a Form 13D on Valeant Pharmaceuticals Intl Inc. (NYSE:VRX). The filing shows that Pershing Square owns 30.71 million shares of the beleaguered pharmaceutical company, unchanged from a filing issued by Ackman’s firm in early February. More importantly, the filing reveals that Valeant recently added three independent directors to its board, including Pershing Square’s Vice Chairman Stephen Fraidin.
Item 4 of the filing was updated with the following information:
On March 9, 2016, the Issuer announced that its board of directors (the Board) appointed Stephen Fraidin, Vice Chairman of Pershing Square, as well as Fred Eshelman and Thomas W. Ross, Jr., as independent directors, effective immediately.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Pershing Square Capital Management | 0 | 30,711,122 | 0 | 30,711,122 | 30,711,122 | 9.0% |
| PS Management GP | 0 | 30,711,122 | 0 | 30,711,122 | 30,711,122 | 9.0% |
| William A. Ackman | 0 | 30,711,122 | 0 | 30,711,122 | 30,711,122 | 9.0% |
Follow Bill Ackman's Pershing Square
Page 1 of 7 SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
VALEANT
PHARMACEUTICALS INTERNATIONAL, INC.
(Name of Issuer)
Common Stock
(Title of
Class of Securities)
91911K102
(CUSIP Number)
Steve
Fraidin
Steve Milankov
Pershing Square Capital Management, L.P.
888 Seventh Avenue, 42nd Floor
New York, New York 10019
212-813-3700
With a
Copy to:
Richard M. Brand
Cadwalader, Wickersham & Taft LLP
One World Financial Center
New York, NY 10281
212-504-5757
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
March 8, 2016
(Date of Event Which Requires Filing of This Statement)
If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other
parties to whom copies are to be sent.
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
